FACULTAD DE ODONTOLOGÍA
Facultad
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (11)
2021
-
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
ESMO Open, Vol. 6, Núm. 2
-
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
ESMO open, Vol. 6, Núm. 4, pp. 100215
-
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept
Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1520-1528
2020
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2019
-
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 55-63
-
The Medical Oncology resident mentor: situation and workload
Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 304-313
2016
-
SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1172-1178
2014
-
Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 243-256
2013
2010
-
SEOM clinical guidelines for the adjuvant treatment of colorectal cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 724-728
2009
-
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144